Irreversible ototoxicity associated with zalcitabine.
Monte
S
S
Department of Genitourinary Medicine, General Infirmary at Leeds, UK.
Fenwick
J D
JD
Monteiro
E F
EF
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D003638:Deafness / Q000139:chemically induced* / Q000175:diagnosis*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*
D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D016047:Zalcitabine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination